Drug utilization and asthma control among young Danish adults with asthma: Analyses of trends and determinants

Danish Medical Journal

Volumn 59, Issue 8, 2012, Pages

  Davidsen, Jesper Rømhild ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DENMARK; DRUG USE; DRUG UTILIZATION; EDUCATION; HUMAN; INCOME; OUTCOME VARIABLE; PREVALENCE; QUESTIONNAIRE; RHINITIS; SOCIAL STATUS; ADOLESCENT; ADULT; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; SOCIOECONOMICS; STATISTICS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; DENMARK; DRUG PRESCRIPTIONS; HUMANS; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84873243604     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (182)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. WHO/NHLBI workshop report. Updated 2009. National Heart, Lung and Blood Institute. Available at, http://www.ginasthma.com/.
2. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004;10(1):44-50.
3. van Staa TP, Cooper C, Leufkens HG, Lammers JW, Suissa S. The use of inhaled corticosteroids in the United Kingdom and the Netherlands. Respir Med 2003;97(5):578-85.
4. Janson C, de Marco R, Accordini S, Almar E, Bugiani M, Carolei A, et al. Changes in the use of anti-asthmatic medication in an international cohort. Eur Respir J 2005;26(6): 1047-55.
5. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16(5):802-7.
6. de Marco R, Cazzoletti L, Cerveri I, Corsico A, Bugiani M, Accordini S, et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 2005;138(3):225-34.
7. FitzGerald JM, Boulet LP, McIvor RA, Zimmerman S, Chapman KR. Asthma control in Canada remains subop-timal: the Reality of Asthma Control (TRAC) study. Can Respir J 2006;13(5):253-9.
8. National Asthma Education an d Prevention Programme. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. NIH Publication No. 07-4051. Bethesda MD: National Heart, Lung and Bloo d Institute. Available at, http://www.nhlbi.nih.gov/guid elines/asthma/asthg dln. pdf; August2007.
9. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010;125(3):600-8.
10. Andersen M, Kragstrup J, Sond ergaard J. How cond uct-ing a clinical trial affects physicians' guid eline ad herence and d rug preferences. JAMA 2006;295(23):2759-64.
11. Furu K, Wettermark B, Andersen M, Martikainen JE, Al-marsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepid emiological research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94.
12. Gaist D, Hallas J, Hansen NC, Gram LF. Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Br J Clin Pharmacol 1996;41(4):285-9.
13. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469-78.
14. Mossing R, Nielsen GD. Cost-of-illness of asthma in Denmark in the year 2000. Ugeskr Laeger 2003;165(26):2646-9.
15. Kynyk JA, Mastronar de JG, McCallister JW. Asthma, the sex difference. Curr Opin Pulm Med 2011;17(1):6-11.
16. Fanta CH. Asthma. N Engl J Med 2009;360(10):1002-14.
17. Peat JK. Asthma: a longitud inal perspective. J Asthma 1998;35(3):235-41.
18. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82(3):233-48.
19. World wide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopiceczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351(9111): 1225-32.
20. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996;9(4):687-95.
21. Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol 1997;100(6 Pt 1):S2-24.
22. Arshad SH. Does exposure to ind oor allergens contribute to the d evelopment of asthma and allergy? Curr Allergy Asthma Rep 2010;10(1):49-55.
23. Thomsen SF, Ulrik CS, Kyvik KO, Larsen K, Skadhauge LR, Steffensen I, et al. The inci d ence of asthma in young adults. Chest 2005;127(6):1928-34.
24. Peden DB. The epid emiology and genetics of asthma risk associated with air pollution. J Allergy Clin Immunol 2005;115(2):213-9.
25. Strachan DP. Hayfever, hygiene, and household size. BMJ 1989;299(6710): 1259-60.
26. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364(8):701-9.
27. Braun-Fahrlander C, Gassner M, Grize L, Takken-Sahli K, Neu U, Stricker T, et al. No further increase in asthma, hay fever and atopic sensitisation in adolescents living in Switzerland. Eur Respir J 2004;23(3):407-13.
28. Toelle BG, Ng K, Belousova E, Salome CM, Peat JK, Marks GB. Prevalence of asthma and allergy in school-children in Belmont, Australia: three cross sectional surveys over 20 years. BMJ 2004;328(7436):386-7.
29. Browatzki A, Ulrik CS, Lange P. Prevalence and severity of self-reported asthma in young adults, 1976-2004. Eur Respir J 2009;34(5): 1046-51.
30. Hansen EF, Rappeport Y, Vestbo J, Lange P. Increase in prevalence and severity of asthma in young adults in Copenhagen. Thorax 2000;55(10):833-6.
31. Thomsen SF, Ulrik CS, Larsen K, Backer V. Change in prevalence of asthma in Danish children and adolescents. Ann Allergy Asthma Immunol 2004;92(5):506-11.
32. von Linstow ML, Porsbjerg C, Ulrik CS, Nepper-Christensen S, Backer V. Prevalence and predictors of atopy among young Danish adults. Clin Exp Allergy 2002;32(4):520-5.
33. Skadhauge LR, Baelum J, Siersted HC, Sherson DL, Dahl S, Thomsen GF, et al. The occurrence of asthma among young adults. A population-based study in five west Danish counties. Ugeskr Laeger 2005;167(6):648-51.
34. Gross NJ. What is this thing called love?--or, defining asthma. Am Rev Respir Dis 1980;121(2):203-4.
35. Burney P. Interpretation of epid emiological surveys of asthma. Ciba Found Symp 1997;206:111-8.
36. Pekkanen J, Pearce N. Defining asthma in epid emiological studies. Eur Respir J 1999;14(4):951-7.
37. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur RespirJ 2008;31(1):143-78.
38. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, et al. Indirect airway challenges. Eur RespirJ 2003;21(6):1050-68.
39. British Guideline on the Management of Asthma. Thorax 2008;63 Suppl 4:iv1-121.
40. Sakula A. A history of asthma. The FitzPatrick lecture 1987. J R Coll Physicians Lond 1988;22(1):36-44.
41. Gay LN, Long JW. Clinical evaluation of isopropyl-epinephrine in management of bronchial asthma. J Am Med Assoc 1949;139(7):452-7.
42. Lands AM, Luduena FP, Hoppe JO, Oyen IH. The pharmacologic actions of the bronchodilator drug, isoetharine. J Am Pharm Assoc Am Pharm Assoc (Baltim) 1958;47(10):744-8.
43. Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol: a new, selective beta-ad renoceptive receptor stimulant. Br J Pharmacol 1969;35(1):141-51.
44. Hedstrand U. The effect of a new sympathomimetic be-ta-receptor stimulating drug (terbutaline) on the pulmonary mechanics in bronchial asthma. Scand J Respir Dis 1970;51(3): 188-94.
45. Castro M, Kraft M. Broncho dilators: Beta2-agonists and anticholinergics. Clinical asthma. Philad elphia: Mosby, Elsevier; 2008. p. 241-50.
46. Sears MR, Lotvall J. Past, present and future--beta2-ad renoceptor agonists in asthma management. Respir Me d 2005;99(2): 152-70.
47. Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy 2004;3(3):271-7.
48. Ulrik CS. Indacaterol is a new once-daily beta2-agonist for treatment of COPD. Ugeskr Laeger 2010;172(47):3260-3.
49. Kaplan A, Ryan D. The role of budesoni d e/formoterol for maintenance and relief in the management of asthma. Pulm Pharmacol Ther 2010;23(2):88-96.
50. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'byrne P, Barnes PJ, et al. Effect of inhaled formoterol and bud esonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20): 1405-11.
51. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153(5):1481-8.
52. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007;119(2):344-50.
53. Lotvall J. The long and short of beta2-agonists. Pulm Pharmacol Ther 2002;15(6):497-501.
54. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the antiinflammatory effect of low-dose budesoni de plus formoterol versus high-dose budesoni de in asthma. Am J Respir Crit Care Med 2000;161(3 Pt 1):996-1001.
55. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med 2005;99(10): 1263-7.
56. O'Byrne PM, Bisgaard H, God ard PP, Pistolesi M, Palm-qvist M, Zhu Y, et al. Budesonide formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171(2): 129-36.
57. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesoni de in combination with formoterol for reliever therapy in asthma exacerbations: a rand omise d controlled, double-blind study. Lancet 2006;368(9537):744-53.
58. Schwartz E. Oral cortisone in intractable bronchial asthma; preliminary report. J Allergy 1951;22(1):1-3.
59. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J 1972;1(5800):585-90.
60. Castro M, Kraft, M. Corticosteroids. Clinical asthma. 1st edition ed. Philadelphia: Mosby, Elsevier; 2008. p. 25162.
61. Danish Medicines Agency. Available at, http://www.medstat.dk/.
62. Angus RM. Inhaled corticosteroids (budesonide): the cornerstone of asthma therapy--what are the options? Pulm Pharmacol Ther 2002;15(6):479-84.
63. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148(3):245-54.
64. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157(3 Pt 2):S1-53.
65. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332(13):868-75.
66. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002;15(1):35-50.
67. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142(4):832-6.
68. Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 1990;141(2 Pt 2):S70-S76.
69. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. Eur Respir J 1999;13(4):904-18.
70. Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006;61(2):100-4.
71. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179(1):19-24.
72. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277(11):887-91.
73. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007;62(6):611-9.
74. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'byrne P, et al. GINA guidelines on asthma and beyond. Allergy 2007;62(2):102-12.
75. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. WHO/NHLBI workshop report. Up dated 2006. National Heart, Lung and Blood Institute. Available at, http://www.ginasthma.com/.
76. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. WHO/NHLBI workshop report. Updated 2008. National Heart, Lung and Blood Institute. Available at, http://www.ginasthma.com/.
77. Humbert M, Holgate S, Boulet LP, Bousquet J. Asthma control or severity: that is the question. Allergy 2007;62(2):95-101.
78. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996;98(6 Pt 1):1016-8.
79. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170(8):836-44.
80. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. World wide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40-7.
81. Vermeire PA, Rabe KF, Soriano JB, Maier WC. Asthma control an d d ifferences in management practices across seven European countries. Respir Med 2002;96(3):142-
82. Backer V, Nolte H, Pedersen L, Dam N, Harving H. Unawareness and und ertreatment of asthma: follow-up in a different geographic area in Denmark. Allergy 2009;64(8): 1179-84.
83. Nolte H, Nepper-Christensen S, Backer V. Unawareness and und ertreatment of asthma and allergic rhinitis in a general population. Respir Med 2006;100(2):354-62.
84. Backer V, Ulrik CS, Harving H, Lange P, Soes-Petersen U, Plaschke PP. Management of asthma in adults: d o the patients get what they nee d--and want? Allergy Asthma Proc 2007;28(3):375-81.
85. Bousquet J, Knani J, Henry C, Liard R, Richard A, Michel FB, et al. Und ertreatment in a nonselected population of adult patients with asthma. J Allergy Clin Immunol 1996;98(3):514-21.
86. Cerveri I, Zoia MC, Bugiani M, Corsico A, Carosso A, Piccioni P, et al. Inad equate antiasthma d rug use in the north of Italy. Eur Respir J 1997;10(12):2761-5.
87. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inad equate use of asthma me dication in the Unite d States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002;110(1):58-64.
88. Kandane-Rathnayake RK, Matheson MC, Simpson JA, Tang ML, Johns DP, Meszaros D, et al. Ad herence to asthma management guidelines by midd le-aged adults with current asthma. Thorax 2009;64(12):1025-31.
89. Osterberg L, Blaschke T. Adherence to med ication. N Engl J Me d 2005;353(5):487-97.
90. Horne R. Compliance, ad herence, and concord ance: implications for asthma treatment. Chest 2006;130(1 Suppl):65S-72S.
91. Lasmar L, Camargos P, Champs NS, Fonseca MT, Fontes MJ, Ibiapina C, et al. Adherence rate to inhaled cortico-steroi d s and their impact on asthma control. Allergy 2009;64(5):784-9.
92. Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, De MR. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1999;14(2):288-94.
93. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhale d corticosteroids for asthma therapy: patient compliance, d evices, an d inhalation technique. Chest 2000;117(2):542-50.
94. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, La-fata JE, et al. Relationship between ad herence to inhaled corticosteroids an d poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114(6):1288-93.
95. Williams LK, Joseph CL, Peterson EL, Wells K, Wang M, Chowdhry VK, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonad herence. J Allergy Clin Immunol 2007; 120(5): 1153-9.
96. Ulrik CS, Backer V, Soes-Petersen U, Lange P, Harving H, Plaschke PP. The patient's perspective: adherence or non-adherence to asthma controller therapy? J Asthma 2006;43(9):701-4.
97. Howell G. Nonad herence to med ical therapy in asthma: risk factors, barriers, and strategies for improving. J Asthma 2008;45(9):723-9.
98. Bender BG. Overcoming barriers to nonad herence in asthma treatment. J Allergy Clin Immunol 2002;109(6 Suppl):S554-S559.
99. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100(8):1307-17.
100. Castaldi PJ, Rogers WH, Safran DG, Wilson IB. Inhaler costs and medication nonadherence among seniors with chronic pulmonary d isease. Chest 2010;138(3):614-20.
101. Newcomb PA, McGrath KW, Covington JK, Lazarus SC, Janson SL. Barriers to patient-clinician collaboration in asthma management: the patient experience. J Asthma 2010;47(2):192-7.
102. Gibson PG, Powell H. Written action plans for asthma: an evi d ence-based review of the key components. Thorax 2004;59(2):94-9.
103. Partridge MR, van der MT, Myrseth SE, Busse WW. Atti-tudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
104. Allen-Ramey FC, Samet JM, Rand CS, Joseph CL. Trends in use of inhaled corticosteroid s for asthma management: 1994-1998. Ann Epidemiol 2004;14(3):161-7.
105. Bisgaard H. What drives prescription patterns in pe diat-ric asthma management? J Allergy Clin Immunol 2007;120(4):969-72.
106. Bender BG, Rand C. Medication non-ad herence and asthma treatment cost. Curr Opin Allergy Clin Immunol 2004;4(3):191-5.
107. Pont LG, Denig P, van der MT, van d, V, Haaijer-Ruskamp FM. Validity of performance in d icators for assessing prescribing quality: the case of asthma. Eur J Clin Pharmacol 2004;59(11):833-40.
108. Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C, et al. The socio-economic burden of asthma is substantial in Europe. Allergy 2008;63(1):116-24.
109. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007;120(6):1360-7.
110. Demoly P, Paggiaro P, Plaza V, Bolge SC, Kannan H, So-hier B, et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev 2009; 18(112): 105-12.
111. Fuhlbrigge A, Reed ML, Stempel DA, Ortega HO, Fanning K, Stanford RH. The status of asthma control in the U.S. adult population. Allergy Asthma Proc 2009;30(5):529-33.
112. Boulet LP. Influence of comorbid conditions on asthma. Eur RespirJ 2009;33(4):897-906.
113. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324(7340):763.
114. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R, III, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004;351(11):1068-80.
115. Chaudhuri R, McSharry C, McCoard A, Livingston E, Hothersall E, Spears M, et al. Role of symptoms and lung function in determining asthma control in smokers with asthma. Allergy 2008;63(1):132-5.
116. Busse WW, Lemanske RF, Jr., Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010;376(9743):826-34.
117. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000;16(3):432-6.
118. Shore SA. Obesity and asthma: implications for treatment. Curr Opin Pulm Med 2007;13(1):56-62.
119. Nelson-Piercy C. Asthma in pregnancy. Thorax 2001;56(4):325-8.
120. Hallas J, Hansen NC. Individual utilization of anti-asthma medication by young adults: a prescription database analysis. J Intern Med 1993;234(1):65-70.
121. Klomp H, Lawson JA, Cockcroft DW, Chan BT, Cascagnet-te P, Gander L, et al. Examining asthma quality of care using a population-based approach. CMAJ 2008; 178(8): 1013-21.
122. Weidinger P, Nilsson JL, Lindblad U. Adherence to diagnostic guidelines and quality indicators in asthma and COPD in Swedish primary care. Pharmacoepidemiol Drug Saf 2009;18(5):393-400.
123. Calverley PM. Effect of corticosteroids on exacerbations of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004;1(3):161-6.
124. Regidor E. Social determinants of health: a veil that hides socioeconomic position and its relation with health. J Epidemiol Community Health 2006;60(10):896-901.
125. Dalton SO, Steding-Jessen M, Gislum M, Frederiksen K, Engholm G, Schuz J. Social inequality and incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Background, aims, material and methods. Eur J Cancer 2008;44(14):1938-49.
126. Ellison-Loschmann L, Sunyer J, Plana E, Pearce N, Zock JP, Jarvis D, et al. Socioeconomic status, asthma and chronic bronchitis in a large community-based study. Eur Respir J 2007;29(5):897-905.
127. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L, et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health 2007;61(12):1091-7.
128. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005;60(5):534-42.
129. Lynd LD, Sandford AJ, Kelly EM, Pare PD, Bai TR, FitzGerald JM, et al. Reconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. Chest 2004;126(4):1161-8.
130. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med 1998;157(6 Pt 1):1810-7.
131. Janson SL, Earnest G, Wong KP, Blanc PD. Predictors of asthma medication nonadherence. Heart Lung 2008;37(3):211-8.
132. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44(4):445-8.
133. Christiansen T. Organization and financing of the Danish health care system. Health Policy 2002;59:107-18.
134. Pedersen KM. Pricing and reimbursement of drugs in Denmark. Eur J Health Econ 2003;4:60-5.
135. Statistics Denmark. Available at, http://www.dst.dk/.
136. WHO Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs. Oslo: Norwegian Institute of Public Health; 2008.
137. WHO Collaboration Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: Norwegian Institute of Public Health; 2010.
138. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14(4):902-7.
139. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99(5):553-8.
140. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100(4):616-21.
141. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006;333(7571):726.
142. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur RespirJ 2005;26(2):319-38.
143. Institute of Rational Pharmacotherapy (IRF). Available at, http://www.irf.dk/dk/anmeldelser/praeparatanmeldelser/arkiv/onbrez.htm/.
144. Rothman KJ, Greenland S, Lash TL. Modern Epid emiology. 3rd edition ed. Philad elphia: Lippincott Williams & Wilkins; 2008.
145. Altman DG. Practical statistics for medical research. 1st edition ed. Lond on: Chapman & Hall/CRC; 1999.
146. Stovring H. New biostatistical metho d s in general practice research. A literature review. Ugeskr Laeger 2002;164(46):5399-402.
147. Rothman K. Epid emiology: An introduction. Oxford: Oxford University Press; 2002.
148. Sørensen HT, Steffensen FH, Ejlersen E, Møller-Petersen J, Kristensen K. Research in the Danish health service system: completeness and validity of prescription data, illustrate d by analysis utilization of oral anticoagulants. Int J Risk Saf Med 1995;7:33-41.
149. Blais L, Kettani FZ, Beauchesne MF, Lemiere C, Perreault S, Forget A. New measure of ad herence adjuste d for prescription patterns: the case of adults with asthma treate d with inhaled corticosteroid monotherapy. Ann Pharmacother 2011;45(3):335-41.
150. Sondergaard J, Andersen M, Vach K, Kragstrup J, Maclure M, Gram LF. Detaile d postal feed back about prescribing to asthma patients combined with a guide-line statement showed no impact: a rand omised controlled trial. Eur J Clin Pharmacol 2002;58(2):127-32.
151. Thygesen L. The register-based system of d emographic and social statistics in Denmark-an overview. Stat J UN Econ Commun Eur 1995;12:49-55.
152. Revicki D, Weiss KB. Clinical assessment of asthma symptom control: review of current assessment instruments. J Asthma 2006;43(7):481-7.
153. Halbert RJ, Tinkelman DG, Globe DR, Lin SL. Measuring asthma control is the first step to patient management: a literature review. J Asthma 2009;46(7):659-64.
154. de Vet HC, Terwee CB, Knol DL, Bouter LM. When to use agreement versus reliability measures. J Clin Epidemiol 2006;59(10): 1033-9.
155. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004;113(1):59-65.
156. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followe d by asthma specialists. J Allergy Clin Immunol 2006;117(3):549-56.
157. Andersen M. Is it possible to measure prescribing quality using only prescription data? Basic Clin Pharmacol Toxicol 2006;98(3):314-9.
158. Pont LG, van der Werf GT, Denig P, Haaijer-Ruskamp FM. Identifying general practice patients diagnosed with asthma and their exacerbation episodes from prescribing data. Eur J Clin Pharmacol 2002;57(11):819-25.
159. Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assesse d by questionnaires. A literature review. Chest 1993;104(2):600-8.
160. Ronmark E, Lundqvist A, Lundback B, Nystrom L. Nonresponders to a postal questionnaire on respiratory symptoms and d iseases. Eur J Epidemiol 1999;15(3):293-9.
161. Moth G, Vedsted P, Schiotz P. Id entification of asthmatic children using prescription data and diagnosis. Eur J Clin Pharmacol 2007;63(6):605-11.
162. Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic me d ications as a proxy for prevalence of asthma in children and ad olescents in Norway: a na-tionwid e prescription database analysis. Eur J Clin Pharmacol 2007;63(7):693-8.
163. Kanervisto M, Vasankari T, Laitinen T, Heliovaara M, Jousilahti P, Saarelainen S. Low socioeconomic status is associated with chronic obstructive airway diseases. Respir Med 2011; 105(8): 1140-6.
164. Statistikbanken. Available at, http://www.statistikbanken.dk/.
165. Fabricius P, Lokke A, Marott JL, Vestbo J, Lange P. Prevalence of COPD in Copenhagen. Respir Med 2011;105(3):410-7.
166. Heitmann BL. Occurrence and d evelopment of overweight and obesity among ad ult Danes age d 30-60 years. Ugeskr Laeger 1999;161(31):4380-4.
167. Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med 2006;100(4):648-57.
168. Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med 2007;101(11):2240-7.
169. Gilman SE, Abrams DB, Buka SL. Socioeconomic status over the life course and stages of cigarette use: initiation, regular use, and cessation. J Epidemiol Community Health 2003;57(10):802-8.
170. Turner S, Thomas M, von ZJ, Price D. Prescribing trends in asthma: a longitudinal observational study. Arch Dis Child 2009;94(1):16-22.
171. Arnlind MH, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson EW. Regional variation and adherence to guidelines for drug treatment of asthma. Eur J Clin Pharmacol 2010;66(2):187-98.
172. Diette GB, Wu AW, Skinner EA, Markson L, Clark RD, McDonald RC, et al. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999;159(22):2697-704.
173. Sundberg R, Toren K, Franklin KA, Gislason T, Omenaas E, Svanes C, et al. Asthma in men and women: Treatment adherence, anxiety, and quality of sleep. Respir Med 2010;104(3):337-44.
174. Sexton M, Althuis MD, Santanello N, Hyndman S, Williams R, Schmeidler D. Sex differences in the use of asthma drugs: cross sectional study. BMJ 1998;317(7170): 1434-7.
175. Naleway AL, Vollmer WM, Frazier EA, O'Connor E, Magid DJ. Gender differences in asthma management and quality of life. J Asthma 2006;43(7):549-52.
176. Basagana X, Sunyer J, Kogevinas M, Zock JP, Duran-Tauleria E, Jarvis D, et al. Socioeconomic status and asthma prevalence in young adults: the European Community Respiratory Health Survey. Am J Epidemiol 2004; 160(2): 178-88.
177. Eagan TM, Gulsvik A, Eide GE, Bakke PS. The effect of educational level on the incidence of asthma and respiratory symptoms. Respir Med 2004;98(8):730-6.
178. Hedlund U, Eriksson K, Ronmark E. Socio-economic status is related to incidence of asthma and respiratory symptoms in adults. Eur Respir J 2006;28(2):303-10.
179. Ekerljung L, Sundblad BM, Ronmark E, Larsson K, Lundback B. Incidence and prevalence of adult asthma is associated with low socio-economic status. Clin Respir J 2010;4(3):147-56.
180. de Vries MP, van den Bemt L, Lince S, Muris JW, Thoonen BP, van Schayck CP. Factors associated with asthma control. J Asthma 2005;42(8):659-65.
181. Lynd LD, Guh DP, Pare PD, Anis AH. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest 2002; 122(6): 1973-81.
182. Laforest L, Van GE, Devouassoux G, Bousquet J, Chretin S, Bauguil G, et al. Influence of patients' characteristics and disease management on asthma control. J Allergy Clin Immunol 2006;117(6):1404-10.